Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479650 | 0.89 | MEN1 (0.54) | ADORA3KMT2ALMNAMEN1NPC1 | |
| Ammonia Solution, Strong SCHEMBL27511086 | 0.83 | ADORA3 (0.50) | ADORA3KMT2AKDM4ELMNAHPGD | |
| SCHEMBL5254988 | 0.83 | ADORA3 (0.53) | ADORA3KMT2ALMNAMEN1NPC1 | |
| SCHEMBL29371671 | 0.83 | ADORA3 (0.53) | ADORA3KMT2ALMNAMEN1NPC1 | |
| SCHEMBL6479836 | 0.82 | ALDH1A1 (0.54) | KMT2AKDM4ELMNAHPGDMEN1 | |
| SCHEMBL6478489 | 0.82 | LMNA (0.45) | ADORA3KMT2AKDM4ELMNAHPGD | |
| SCHEMBL6480019 | 0.82 | ADORA3 (0.48) | ADORA3KMT2AKDM4ELMNAHPGD | |
| SCHEMBL6613383 | 0.82 | CTNNB1 (0.47) | KMT2ALMNAMEN1ALDH1A1POLB | |
| SCHEMBL6648902 | 0.81 | CTNNB1 (0.49) | KMT2ALMNAHPGDMEN1NPC1 | |
| SCHEMBL6480432 | 0.78 | KISS1R (0.49) | ADORA3KMT2AKDM4ELMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390349-B1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | claimed |
| US-6969723-B2 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI - AVENTIS (FR) | 2005-11-29 | — | — | US | claimed |
| US-20040186133-A1 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI (FR) | 2004-09-23 | — | — | US | claimed |
| EP-1390349-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | Sanofi-Aventis (FR) | 2004-02-25 | — | — | EP | claimed |
| WO-2002096879-A9 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SYNTHELABO (FR) | 2003-11-20 | — | — | WO | claimed |
| WO-2002096879-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-12-05 | — | — | WO | claimed |
| EP-1390349-B1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | disclosed |
| CN-1257160-C | Aminoquinoline derivatives and their use as adenosine A3 ligands | PASTEUR SANOFI DIAGNOSTICS (FR) | 2006-05-24 | — | — | CN | disclosed |
| US-6969723-B2 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI - AVENTIS (FR) | 2005-11-29 | — | — | US | disclosed |
| US-20040186133-A1 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI (FR) | 2004-09-23 | — | — | US | disclosed |
| CN-1512985-A | Aminoquinoline and aminopiperidine derivatives and their use as adenosine A3 ligands | ��ŵ�Ѻϳ�ʵ���� | 2004-07-14 | — | — | CN | disclosed |
| EP-1390349-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | Sanofi-Aventis (FR) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002096879-A9 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SYNTHELABO (FR) | 2003-11-20 | — | — | WO | disclosed |
| WO-2002096879-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186133-A1 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | ADORA3, ADORA1, ADORA2A | ADORA3 1/4885KMT2A 2739/4885KDM4E 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.